Navigation Links
Pharmasset to Present at Three Investor Conferences in November 2007
Date:10/26/2007

play of the webcast will be available on Pharmasset's website for a limited period of time following each conference. The investor presentation will be available for download in PDF format following the presentation in the "Events & Presentations" section of the Investor Center on Pharmasset's website at http://investor.pharmasset.com/events.cfm.

About Pharmasset

Pharmasset is a clinical-stage pharmaceutical company committed to discovering, developing and commercializing novel drugs to treat viral infections. Pharmasset's primary focus is on the development of oral therapeutics for the treatment of hepatitis B virus (HBV), hepatitis C virus (HCV) and human immunodeficiency virus (HIV).

Pharmasset is currently developing three product candidates. Clevudine, for the treatment of chronic HBV infection, is enrolling Phase 3 clinical trials for registration in the Americas and Europe. Clevudine is already approved for HBV in South Korea and marketed by Bukwang Pharmaceuticals in South Korea under the brand name Levovir. R7128, an oral treatment for chronic HCV infection, is enrolling a 28-day Phase 1 clinical trial in combination with Pegasys(R) and Copegus(R) through a strategic collaboration with Roche. Racivir, which is being developed for the treatment of HIV in combination with other approved HIV drugs, has completed a Phase 2 clinical trial.

Pegasys(R) and Copegus(R) are registered trademarks of Roche.

Contact

Alan Roemer, Vice President

Investor Relations & Corporate Communications

alan.roemer@pharmasset.com

Office: (609) 613-4125


'/>"/>
SOURCE Pharmasset, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Amplification of genome-representative DNA from limited sources with GenomePlex WGA technology for use in genetic alterations studies
2. Wisconsin firms to present at Cleantech venture capital event
3. New Sonic Foundry search engine finds words, phrases in video presentations
4. Lone Wisconsin firm to present at InvestMidwest
5. Sonic Foundry creates search engine for 7,000 expert video presentations
6. InvestMidWest calls for business presentations
7. Wicab to present BrainPort at Boston conference
8. Three more Wisconsin firms to present at venture forum
9. Six Wisconsin firms to present at BIO Mid-America VentureForum
10. New Health and Human Services representative for Midwest
11. Top 20 big pharmas represent majority of world pharma market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2014)... (PRWEB) August 31, 2014 This ... current state of the Epoxy Hardener industry ... basic overview of the industry, including definitions, applications ... Chinese domestic market analysis are provided with a ... of the market. A comparison between the international ...
(Date:8/29/2014)... -- Pfenex Inc. (NYSE MKT: PFNX), a clinical-stage biotechnology ... difficult to manufacture proteins including biosimilar therapeutics, today ... for the second quarter ended June 30, 2014. ... initial public offering, we have the capital to ... from our proprietary protein expression platform," stated Bertrand ...
(Date:8/29/2014)... (PRWEB) August 29, 2014 The ... $5.6 billion in 2019. It is expected to ... to 2019, and was valued at $1.8 billion ... by Transparency Market Research. , For more information ... http://www.transparencymarketresearch.com/companion-diagnostics-market.html . , The research report, titled “Companion ...
(Date:8/29/2014)... Pittcon is pleased to announce that the ... Horiba Scientific, have organized a session on nanotechnology for ... , Asia’s largest analytical and scientific instruments show, will ... , The four speakers in this U.S. symposium, ... to Single Cells” will present their use of nanotechnology ...
Breaking Biology Technology:Epoxy Hardener Industry Development Trends in Global & China Regions Now Available at ReportsnReports.com 2Epoxy Hardener Industry Development Trends in Global & China Regions Now Available at ReportsnReports.com 3Pfenex Reports Second Quarter 2014 Results and Provides Business Update 2Pfenex Reports Second Quarter 2014 Results and Provides Business Update 3Pfenex Reports Second Quarter 2014 Results and Provides Business Update 4Pfenex Reports Second Quarter 2014 Results and Provides Business Update 5Pfenex Reports Second Quarter 2014 Results and Provides Business Update 6Pfenex Reports Second Quarter 2014 Results and Provides Business Update 7Pfenex Reports Second Quarter 2014 Results and Provides Business Update 8Companion Diagnostics Market to Hit $5.6 Billion in 2019: Transparency Market Research 2Companion Diagnostics Market to Hit $5.6 Billion in 2019: Transparency Market Research 3Fifth Annual U.S. Symposium at JASIS Organized by Pittcon’s Program Chairman Hub MacDonald 2
... Aug. 15 BioMaxx Systems Inc. (Other,OTC: BMXSF), ... engagement letter with,Alcofuel Technologies Ltd., for the provision ... micro-refinery. Pursuant to the engagement,letter, Alcofuel Technologies has ... engagement letter, to design and manufacture a small,scale ...
... Inc. (Nasdaq: ADLS ), today announced that ... informed the Company that the,market value of its ... days, which is the requirement for continued listing ... 4450(b)(1)(A). Nasdaq,also informed the Company that it is ...
... - AEterna Zentaris Inc.,(TSX: AEZ; NASDAQ: AEZS), a ... today announced the filling of a key,position completing ... Blake,M.D., as Senior Vice President and Chief Medical ... timely and critical as our foremost,priority is to ...
Cached Biology Technology:BioMaxx Systems Inc. Signs Engagement Letter With Alcofuel Technologies for Provision of an Ethanol Micro-Refinery 2Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter 2Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter 3Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter 4AEterna Zentaris completes management team with the appointment of Chief Medical Officer 2AEterna Zentaris completes management team with the appointment of Chief Medical Officer 3
(Date:9/2/2014)... American Society of Human Genetics (ASHG) and the ... the National Institutes of Health, have named Katherine ... in Chicago, the newest ASHG/NHGRI Genetics and Public ... The Genetics and Public Policy Fellowship is intended ... genetics-related health and research policy at a national ...
(Date:9/2/2014)... published paper provides a history of scientific research ... wildlife in these systems, and sets an agenda ... , The paper, "Mountain gloom and mountain glory ... change in mountain regions," appears online in the ... Charles C. Chester of Tufts University, Jodi A. ...
(Date:9/2/2014)... A team of University of Maryland physicists has ... scientists say make possible new nanostructures and nanotechnologies ... and quantum computing advances to new sensor development. ... Nature Communications the Maryland scientists, primary ... hybrid nanostructures that uses a connector, or "intermedium," ...
Breaking Biology News(10 mins):ASHG and NHGRI award genetics and public policy fellowship 2An uphill climb for mountain species? 2An uphill climb for mountain species? 3New synthesis method may shape future of nanostructures, clean energy 2New synthesis method may shape future of nanostructures, clean energy 3
... Darwin based his groundbreaking theory of natural selection on ... key to evolution. Some individuals are better adapted ... likely to survive and pass on their genes to ... the first place still poses somewhat of a puzzle ...
... Springer to publish its official English-language journal, Human Cell ... published at Springer in early 2011. The journal was ... as a forum for international research on all aspects of ... of studies using ES/iPS cells or tissue stem cells derived ...
... study shows for the first time that the three ... disrupt a molecular network that includes several important genes ... research was led by investigators at the Ohio State ... Hospital and Richard J. Solove Research Institute (OSUCCC ...
Cached Biology News:Evolution by mistake 2Evolution by mistake 3Evolution by mistake 4Human Cell joins Springer's publishing program 2Molecular network influences development of chronic lymphocytic leukemia 2
ANTI-RAT ADHESION MARKERS, CDs, CYTOKINES, ETC Rat ICAM PE - Mouse IgG1...
Mouse monoclonal [050-04] to C2 ( Abpromise for all tested applications). entrezGeneID: 717 SwissProtID: P06681...
Reacts with methylated DNA from plants and vertebrates...
Rabbit polyclonal to Bag5 ( Abpromise for all tested applications). entrezGeneID: 9529 SwissProtID: Q9UL15...
Biology Products: